Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: A First-in-Class Selective EGFR and PI3K Inhibitor Enables Single-Molecule Targeting of Adaptive Resistance

  • By

  • Christopher E. Whitehead

  • Elizabeth K. Ziemke

  • Christy L. Frankowski-McGregor

  • Rachel A. Mumby

  • June Chung

  • Jinju Li

  • Nathaniel Osher

  • Oluwadara Coker

  • Veerabhadran Baladandayuthapani

  • Scott Kopetz

  • Judith S. Sebolt-Leopold

  • October 12, 2026

Share

Objective:

Correct duplicated insulin ELISA measurements in Fig. 6b and its associated source data file.

Approach:
  • Correction: Three measurements were inadvertently duplicated during transfer of mouse serum insulin ELISA values from the original plate-reader data file.
  • Amendment: Fig. 6b and its source data file were amended to show the full set of original measurements from samples obtained from six mice.
Key Findings:
  • The initial published version contained three duplicated measurements in Fig. 6b and its associated source data file.
Interpretation:

The correction updates the figure and source data to reflect the original measurements.

Conclusion:

The correction was published online on 11 July 2024.

Sources:

Original Source(s)

Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

  • by Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel A. Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S. Sebolt-Leopold

  • October 12, 2026

Related Content

Building a Pre-Disease Data Map

Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear

  • October 7, 2026

  • 2 min
2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.

  • October 15, 2026

  • 1 min
Comment on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation”